Clinical trials: sponsored by Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
oral administration of Tegio capsules for 12 months for NPC patients with high risk of metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant metastasis，safety was also evaluated.
- Trial name
- NCT03904225
- Testing
- Tegafur-Gimeracil-Oteracil
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
There is no currently available treatment for peritoneal metastasis of gastric cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) can not only maintain the high concentration of drugs in the abdominal cavity, but also…
- Trial name
- NCT04889768
- Testing
- HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Gray Zone Lymphoma, Relapse/Recurrence
A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma
There are no standard chemotherapy regimens for relapse/refractory gray area lymphoma. The programmed cell death ligand 1 (PD-L1) encoding gene is located in 9p24.1, so it is speculated that the programmed cell death pathway…
- Conditions
- Gray Zone Lymphoma, Relapse/Recurrence, Chemotherapy Effect
- Trial name
- NCT04860674
- Testing
- PD-1 inhibitor +ICE
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect
Rituximab Combined With Chidamide and Lenalidomide for r/r AITL
This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- AITL (NCT04319601)
- Testing
- Rituximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
The purpose of this study is to explore the efficacy and safety of Toripalimab injection (JS001) given before and after concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04084158
- Testing
- Toripalimab injection (JS001), Paclitaxel, Albumin-Bound, Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Malignant Brain Stem Tumor, Glioma
Anlotinib to Malignant Brainstem Glioma
This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma.
- Trial name
- NCT04668508
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and Pertuzumab given as neoadjuvant treatment…
- Trial name
- NCT04665986
- Testing
- Navelbine, Docetaxel
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Rectal Cancer
Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer
This is a single arm, open-label, prospective phase II clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and immunotherapy (PD-1 antibody) for patients with locally advanced rectal cancer (LARC).
- Trial name
- NCT04663763
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Reflux Esophagitis
Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy
In the past years, the adenocarcinoma of the esophagogastric junction (AEG) has been increasing obviously in China. It may be caused by the reason of increased body weight, alcohol consumption, gastroesophageal reflux disease and…
- Trial name
- NCT04657848
- Testing
- proximal gastrectomy combined with Cheng's Giraffe reconstruction
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, HER2
Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer
Preoperative systemic treatment can make patients getting more opportunity for breast-conserving surgery, down-staging and new drugs developing.
- Conditions
- Breast Cancer, HER2, Preoperative Systemic Treatment
- Trial name
- NCT04249440
- Testing
- Preoperative systemic treatment
- Volunteers
- 1,067 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Hepatocellular
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
This is a multicenter, prospective, observational study in which subjects will be treated with lenvatinib combined with TACE in un-resectable HCC patients who had not received systematic treatment or TACE treatment in the past.
- Trial name
- NCT04560751
- Testing
- Lenvatinib, TACE
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Cancer, Neoplasm Metastasis
Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions
Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.
- Trial name
- NCT03129412
- Testing
- radical radiotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Chemoradiation
S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer
This was a randomised, multicenter, phase 3 trial. Patients who were age of 70 years or older with histologically confirmed esophageal cancer were randomly assigned to S-1 concurrent with radiotherapy or radiotherapy alone.The…
- Trial name
- NCT02813967
- Testing
- Radiotherapy 54 Gy, Radiotherapy 60 Gy, S-1
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Zhejiang Cancer Hospital
Small Cell Lung Cancer Limited Stage
A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC
For most of the patients with limited-stage SCLC, thoracic radiotherapy combined with chemotherapy is the standard treatment at present.
- Trial name
- CTV (NCT04543890)
- Testing
- Hyperfractionated radiotherapy, Hypofractionated radiotherapy, Etoposide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
The purpose of this study is to observe and evaluate the efficacy and safety of Camrelizumab combined with or without radiotherapy for the treatment of recurrent or metastatic esophageal cancer that has progressed after…
- Trial name
- NCT04512417
- Testing
- Camrelizumab+Radiotherapy, Camrelizumab
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis
Radiation induced oral mucositis which may result in reduced quality of life is commonly seen during radiotherapy, especially combined with chemotherapy. This study is a prospective, multicenter, and exploratory study.
- Trial name
- NCT03720340
- Testing
- Recombinant Human Interleukin-11, Saline
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer
A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
This is an open-label, single center, non-randomized, phase Ⅱ trial to evaluate safety and efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and Chemotherapy of metastatic colorectal mucinous…
- Trial name
- NCT04446091
- Testing
- Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.), Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Pancreatic Cancer
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
This is an single arm, open-label, phase II trial to evaluate safety and efficacy of using the combination of Camrelizumab with apatinib as second-line therapy for advanced PDAC.
- Trial name
- NCT04415385
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Stomach Cancer
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant…
- Trial name
- NCT04135781
- Testing
- nab paclitaxel, Tegafur, Oxaliplatin
- Where
- China
- Volunteers
- 616 people
- Sponsor
- Zhejiang Cancer Hospital
Biliary Tract Cancer
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract…
- Trial name
- NCT04300959
- Testing
- Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin, Gemcitabine Plus(+)Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital